Royce & Associates LP Has $3.39 Million Stock Position in Accuray Incorporated (NASDAQ:ARAY)

Royce & Associates LP cut its stake in shares of Accuray Incorporated (NASDAQ:ARAY - Free Report) by 34.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,882,369 shares of the medical equipment provider's stock after selling 1,000,167 shares during the quarter. Royce & Associates LP owned 1.88% of Accuray worth $3,388,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ARAY. Los Angeles Capital Management LLC purchased a new stake in shares of Accuray during the third quarter valued at $418,000. US Bancorp DE raised its holdings in Accuray by 1,087.7% during the 3rd quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider's stock worth $32,000 after buying an additional 16,316 shares during the period. Assenagon Asset Management S.A. lifted its stake in Accuray by 127.1% during the third quarter. Assenagon Asset Management S.A. now owns 164,999 shares of the medical equipment provider's stock valued at $297,000 after buying an additional 92,357 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Accuray during the third quarter valued at about $59,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Accuray by 13.3% in the second quarter. The Manufacturers Life Insurance Company now owns 44,936 shares of the medical equipment provider's stock worth $82,000 after buying an additional 5,273 shares during the period. 64.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Accuray from a "buy" rating to a "hold" rating in a report on Friday.

Accuray Stock Up 8.2 %

Accuray stock traded up $0.14 during mid-day trading on Tuesday, hitting $1.84. The company's stock had a trading volume of 737,183 shares, compared to its average volume of 662,347. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. Accuray Incorporated has a 52-week low of $1.40 and a 52-week high of $3.05. The firm's 50 day moving average is $1.85 and its 200 day moving average is $1.83. The company has a market cap of $185.05 million, a PE ratio of -10.82 and a beta of 1.40.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The firm had revenue of $101.55 million for the quarter, compared to the consensus estimate of $98.10 million. During the same period in the previous year, the firm posted ($0.03) earnings per share. On average, analysts anticipate that Accuray Incorporated will post 0.01 earnings per share for the current year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.